ALX-001 is under clinical development by Allyx Therapeutics and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ALX-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALX-001 is under development for the treatment Alzheimer’s disease (AD). The drug candidate is silent allosteric modulator (SAM). It acts by targeting mGLUR5.
Allyx Therapeutics overview
Allyx Therapeutics is a biotechnology company that focuses on the discovery and development of a unique disease modifying treatment for the treatment of Alzheimer’s disease. Allyx Therapeutics is headquartered in New Haven, Connecticut, the US.
For a complete picture of ALX-001’s drug-specific PTSR and LoA scores, buy the report here.